安全COVID-19疫苗的前景展望
本文代表ACTIV工作组评估疫苗与病毒感染(包括冠状病毒)免疫增强疾病的潜在风险及COVID-19疾病新数据。疫苗相关增强疾病在现有疫苗或病毒感染中罕见;动物模型可阐明免疫保护机制,但需在接种候选疫苗人群中观察增强疾病以理解风险。目前免疫学原理和临床前研究均无法为COVID-19候选疫苗的安全性优先排序提供依据,严格的临床试验设计与上市后监测是识别疫苗接种后不良事件(包括COVID-19疾病严重性增强潜力)的可靠策略。
要点
- 疫苗相关增强疾病在现有疫苗或病毒感染中罕见
- 动物模型可阐明免疫保护机制但需人群观察增强疾病
- 当前无法基于安全性对候选疫苗优先排序
核心结论
- 严格的临床试验设计与上市后监测是识别疫苗接种后不良事件(包括COVID-19疾病严重性增强潜力)的可靠策略。
研究设计与样本
- 代表加速COVID-19治疗干预和疫苗(ACTIV)工作组评估疫苗与病毒感染(包括冠状病毒感染)免疫增强疾病潜在风险的研究及COVID-19疾病新数据。
主要发现
- 疫苗相关增强疾病在现有疫苗或病毒感染中罕见。
- 动物模型可阐明SARS-CoV-2感染免疫保护机制,但需在接种候选COVID-19疫苗人群中观察增强疾病以理解风险。
- 目前免疫学原理和临床前研究均无法为COVID-19候选疫苗的安全性优先排序提供依据。
临床怎么用
- 采用严格的临床试验设计并开展上市后监测以识别疫苗接种后不良事件,包括COVID-19疾病严重性增强的潜力。
局限性
- 需在接种候选COVID-19疫苗人群中观察增强疾病才能理解免疫增强风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rapid development of an efficacious vaccine against the viral pathogen severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the cause of the coronavirus disease 2019 (COVID-19) pandemic, is essential, but rigorous studies are required to determine the safety of candidate vaccines. Here, on behalf of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Working Group, we evaluate research on the potential risk of immune enhancement of disease by vaccines and viral infections, including coronavirus infections, together with emerging data about COVID-19 disease. Vaccine-associated enhanced disease has been rarely encountered with existing vaccines or viral infections. Although animal models of SARS-CoV-2 infection may elucidate mechanisms of immune protection, we need observations of enhanced disease in people receiving candidate COVID-19 vaccines to understand the risk of immune enhancement of disease. Neither principles of immunity nor preclinical studies provide a basis for prioritizing among the COVID-19 vaccine candidates with respect to safety at this time. Rigorous clinical trial design and postlicensure surveillance should provide a reliable strategy to identify adverse events, including the potential for enhanced severity of COVID-19 disease, after vaccination.
引用
- Haynes BF, Corey L, Fernandes P, et al. Prospects for a safe COVID-19 vaccine. Sci Transl Med. 2020. PMID: 33077678. doi:10.1126/scitranslmed.abe0948
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。